Jabil is a product solutions company providing comprehensive design, manufacturing, supply chain and product management services. Operating from over 100 facilities in 29 countries, Jabil delivers innovative, integrated and tailored solutions to customers across a broad range of industries and end-markets, such as automotive, consumer lifestyle and wearable tech, defense and aerospace, connected home and building, industrial and energy, enterprise and infrastructure, healthcare, mobility, packaging and printing.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

INTRON CONFIRMS EFFICACY OF CDL200 AGAINST CDI CLINICAL ISOLATES

iNtRON Biotechnology | July 12, 2022

news image

iNtRON Biotechnology announced that CDL200, a novel biological drug candidate under the development of the world's first enteric colon-targeted capsule formulation for the treatment of intractable and recurrent CDI confirmed the strong efficacy against clinical isolates from CDI patients. A company official explained that the antibacterial activity of CDL200 was evaluated for 20 clinical isolates from patients in Europe and Korea, and rapid lysis effect within few minutes afte...

Read More

INTEGRAL MOLECULAR PROVIDES RAPID SAFETY TESTING OF COVID-19 ANTIBODY THERAPEUTICS WITH ITS MEMBRANE PROTEOME ARRAY TECHNOLOGY

Integral Molecular | June 12, 2020

news image

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...

Read More

Medical

MERIDIAN BIOSCIENCE LAUNCHES LYO-READY™ QPCR INHIBITOR TOLERANT BLOOD-SPECIFIC MASTER MIXES FOR DNA & RNA DIRECT DETECTION

Meridian Bioscience, Inc. | March 31, 2022

news image

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy – enabling the earliest detection of cancer using non-invasive liquid biopsy. These two innovative mixes, Lyo-Ready™ Direct DNA qPCR Blood Mix and Lyo-Ready™ Direct RNA/DNA qPCR Blood Mix, are designed for applications that requir...

Read More

Medical

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

news image

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More
news image

Industrial Impact

INTRON CONFIRMS EFFICACY OF CDL200 AGAINST CDI CLINICAL ISOLATES

iNtRON Biotechnology | July 12, 2022

iNtRON Biotechnology announced that CDL200, a novel biological drug candidate under the development of the world's first enteric colon-targeted capsule formulation for the treatment of intractable and recurrent CDI confirmed the strong efficacy against clinical isolates from CDI patients. A company official explained that the antibacterial activity of CDL200 was evaluated for 20 clinical isolates from patients in Europe and Korea, and rapid lysis effect within few minutes afte...

Read More
news image

INTEGRAL MOLECULAR PROVIDES RAPID SAFETY TESTING OF COVID-19 ANTIBODY THERAPEUTICS WITH ITS MEMBRANE PROTEOME ARRAY TECHNOLOGY

Integral Molecular | June 12, 2020

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...

Read More
news image

Medical

MERIDIAN BIOSCIENCE LAUNCHES LYO-READY™ QPCR INHIBITOR TOLERANT BLOOD-SPECIFIC MASTER MIXES FOR DNA & RNA DIRECT DETECTION

Meridian Bioscience, Inc. | March 31, 2022

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy – enabling the earliest detection of cancer using non-invasive liquid biopsy. These two innovative mixes, Lyo-Ready™ Direct DNA qPCR Blood Mix and Lyo-Ready™ Direct RNA/DNA qPCR Blood Mix, are designed for applications that requir...

Read More
news image

Medical

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us